Stimulated Glanzmann’s Thrombasthenia Platelets Produce Microvesicles

Summary

The mechanism of formation of platelet-derived microvesicles remains controversial.

The aim of the present work was to study the formation of microvesicles in view of a possible involvement of the GPIIb-IIIa complex, and of exposure of negatively charged phospholipids as procoagulant material on the platelet surface. This was studied in blood from three Glanzmann’s thrombasthenia patients lacking GPIIb-IIIa and healthy blood donors. MAb FN52 against CD9 which activates the complement system and produces microvesicles due to a membrane permeabilization, ADP (9.37 μM), and the thrombin receptor agonist peptide SFLLRN (100 μM) that activates platelets via G-proteins were used as inducers. In a series of experiments platelets were also preincubated with PGE₁ (20 μM). The number of liberated microvesicles, as per cent of the total number of particles (including platelets), was measured using flow cytometry with FITC conjugated antibodies against GPIIIa or GPIb. Activation of GPIIb-IIIa was detected as binding of PAC-1, and exposure of aminophospholipids as binding of annexin V. With normal donors, activation of the complement system induced a reversible PAC-1 binding during shape change. A massive binding of annexin V was seen during shape change as an irreversible process, as well as formation of large numbers of microvesicles (60.6 ±2.7%) which continued after reversal of the PAC-1 binding. Preincubation with PGE₁ did not prevent binding of annexin V, nor formation of microvesicles (49.5 ± 2.7%), but abolished shape change and PAC-1 binding after complement activation. Thrombasthenic platelets behaved like normal platelets after activation of complement except for lack of PAC-1 binding (also with regard to the effect of PGE₁ and microvesicle formation). Stimulation of normal platelets with 100 μM SFLLRN gave 16.3 ± 1.2% microvesicles, and strong PAC-1 and annexin V binding. After preincubation with PGE₁ neither PAC-1 nor annexin V binding, nor any significant amount of microvesicles could be detected. SFLLRN activation of the thrombasthenic platelets produced a small but significant number of microvesicles (6.4 ± 0.8%). Incubation of thrombasthenic platelets with SFLLRN after preincubation with PGE₁, gave results identical to those of normal platelets. ADP activation of normal platelets gave PAC-1 binding, but no significant annexin V labelling, nor production of microvesicles. Thus, different inducers of the shedding of microvesicles seem to act by different mechanisms. For all inducers there was a strong correlation between the exposure of procoagulant surface and formation of microvesicles, suggesting that the mechanism of microvesicle formation is linked to the exposure of aminophospholipids. The results also show that the GPIIb-IIIa complex is not required for formation of microvesicles after activation of the complement system, but seems to be of importance, but not absolutely required, after stimulation with SFLLRN.

• References

• 1 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-18212
• 2 Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity J Biol Chem 1989; 264: 17049-17057
• 3 Wiedmer T, Shattil S, Cunningham M, Sims PJ. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochem 1990; 29: 623-632
• 4 Holme PA, Brosstad F, Solum NO. The difference between platelet and plasma F XIII used to study the mechanism of platelet microvesicle formation. Thromb Haemost 1993; 70: 681-686
• 5 George JN, Pickett EB, Sauceman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery J Clin Invest 1986; 78: 340-348
• 6 Sandberg H, Bode AP, Dombrose FA, Lentz BR. Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. Thromb Res 1985; 39: 69-79
• 7 Bode AP, Sandberg H, Dombrose FA, Lentz BR. Association of factor V activity with membranous vesicles released from human platelet: requirement for platelet stimulation. Thromb Res 1985; 39: 49-61
• 8 Comfurius P, Senden JM G, Tilly RH J, Schroit AJ, Bevers EM, Zwaal RF A. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026: 153-160
• 9 Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81: 2554-2565
• 10 Monkovic DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem 1990; 265: 17132-17140
• 11 Holme PA, Brosstad F, Solum NO. Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood coagulation and fibrinolysis 1995; 6: 302-310
• 12 Dahlback B, Wiedmer T, Sims PJ. Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticles. Biochem 1992; 31: 12769-12777
• 13 Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648
• 14 Holme PA, Solum NO, Brosstad F, Røger M, Abdelnoor M. Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and Western blotting. Thromb Haemost 1994; 72: 666-671
• 15 Jy W, Horstman L, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-345
• 16 Khan I, Zucker-Franklin D, Karpatkin S. Microthrombocytosis and platelet fragmentation associated with idiopathic/autoimmune thrombocytopenic purpura. Br J Haematol 1975; 31: 449-460
• 17 Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelet and platelet-derived microparticles. Blood 1990; 75: 128-138
• 18 Fox JE B, Austin CD, Reynolds CC, Steffen PK. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266: 13289-13295
• 19 Yano Y, Shiba E, Kambayashi J, Sakon M, Kawasaki T, Fujitani K, Kamg J, Mori T. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. Thromb Res 1993; 71: 385-396
• 20 Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann’s thrombasthenia defect J Biol Chem 1993; 268: 14586-14589
• 21 Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114
• 22 Aakhus AM, Wilkinson JM, Solum NO. Binding of human platelet glycoprotein lb and actin to fragments of actin-binding protein. Thromb Haemost 1992; 67: 252-257
• 23 Goding JW. Conjugation of antibodies with fluorochromes: modification to the standard methods. J Immunol Meth 1976; 13: 216-226
• 24 Lindahl TL, Lundahl J, Netré C, Egberg N. Studies of platelet fibrinogen receptor in Glanzmann patients and uremic patients. Thromb Res 1992; 67: 457-466
• 25 Solum NO, Rubach-Dahlberg E, Pedersen TM, Reisberg T, Høgåsen K, Funderud S. Complement-mediated permeabilization of platelets by monoclonal antibodies to CD9: inhibition by leupeptin, and effects on the GPIb-actin-binding protein system. Thromb Res 1994; 75: 437-452
• 26 Andree HA M, Reutelingsperger CP M, Hauptmann R, Hemker HC, Hermens WT, Willems GM. Binding of vascular anticoagulant (VACα) to planar phospholipid bilayers. J Biol Chem 1990; 265: 4923-4928
• 27 Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944-7949
• 28 Lindahl T, Larsson A. Clq binding to platelets induced by monoclonal antibodies and immune complexes- A flow cytometric analysis. Platelets 1993; 4: 73-77
• 29 Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9 induced shedding of platelet plasma membrane vesicles. Blood 1991; 78: 2880-2886
• 30 Dachary-Prigent J, Pasquet JM, Nurden AT. Ca²⁺-dependence of aminophospholipid exposure, membrane vesiculation and calpain activity on activated platelets. Thromb Haemost 1995; 73: 1053
• 31 Fujimoto T, Fujimura K, Kuramoto A. Electrophysiological evidence that glycoprotein IIb-IIIa complex is involved in calcium channel activation on human platelet membrane. J Biol Chem 1991; 266: 16370-16375